PMID- 23367852
OWN - NLM
STAT- MEDLINE
DCOM- 20130409
LR  - 20190823
IS  - 0387-5911 (Print)
IS  - 0387-5911 (Linking)
VI  - 86
IP  - 6
DP  - 2012 Nov
TI  - [A case of hepatitis B virus/human immunodeficiency virus coinfection in a 
      patient who achived hepatitis B surface antigen seroclearance after interferon 
      therapy followed by antiretroviral therapy without developing immune 
      reconstitution inflammatory syndrome].
PG  - 763-7
AB  - Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) 
      is common worldwide. The current guidelines for the treatment of HIV infection 
      recommend that HIV patients coinfected with HBV receive antiretoroviral therapy 
      (ART) with two nucleoside analogs against HBV. However, an increase in liver 
      enzymes that is usually attributed to HBV immune reconstitution inflammatory 
      syndrome (IRIS) sometimes occurs in HBV/HIV-coinfected patients after the 
      commencement of ART. We report a case of HBV/HIV-coinfection in which the chronic 
      hepatitis B was successfully treated using interferon (IFN) therapy followed by 
      ART without the development of IRIS. A Japanese man in thirties was referred to 
      our hospital because of an acute HIV infection two months after the diagnosis of 
      an acute HBV infection, which had progressed to a chronic HBV infection. The 
      laboratory test results were as follows:hepatitis B surface antigen (HBsAg) 
      positive, hepatitis B e antigen (HBeAg) positive, HBV DNA level of 8.8 Log 
      copies/mL, HBV genotype A, alanine aminotransferase of 834 IU/L, HIV RNA level of 
      5 Log copies/mL, and a CD4+ T cell count of 437/microL. The initial treatment was 
      natural IFNalpha therapy for chronic hepatitis B, and HBeAg seroclearance was 
      achieved 20 weeks after the start of therapy. Four months after the end of IFN 
      therapy for 24 weeks, ART including tenofovir and emtricitabine against HBV was 
      commenced. Six months after starting ART, the patient's serum HBV DNA level had 
      decreased and become undetectable and HBsAg seroclearance was achieved without an 
      elevation in liver enzymes. The present case suggests that IFN therapy prior to 
      ART contributes to a successful outcome for chronic hepatitis B patients 
      coinfected with HIV, if the HIV status does not require the immediate start of 
      ART.
FAU - Mitsumoto, Fujiko
AU  - Mitsumoto F
AD  - Department of General Internal Medicine, Kyushu University Hospital.
FAU - Murata, Masayuki
AU  - Murata M
FAU - Ikezaki, Hiroaki
AU  - Ikezaki H
FAU - Ogawa, Eiichi
AU  - Ogawa E
FAU - Taniai, Hiroaki
AU  - Taniai H
FAU - Toyoda, Kazuhiro
AU  - Toyoda K
FAU - Otaguro, Shigeru
AU  - Otaguro S
FAU - Kainuma, Mosaburo
AU  - Kainuma M
FAU - Okada, Kyoko
AU  - Okada K
FAU - Furusyo, Norihiro
AU  - Furusyo N
FAU - Hayashi, Jun
AU  - Hayashi J
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Kansenshogaku Zasshi
JT  - Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious 
      Diseases
JID - 0236671
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Hepatitis B Antigens)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Adult
MH  - Anti-Retroviral Agents/therapeutic use
MH  - *Coinfection
MH  - HIV Infections/*complications/*therapy
MH  - Hepatitis B Antigens/*analysis
MH  - Hepatitis B, Chronic/*complications/*therapy
MH  - Humans
MH  - Interferons/therapeutic use
MH  - Male
EDAT- 2013/02/02 06:00
MHDA- 2013/04/10 06:00
CRDT- 2013/02/02 06:00
PHST- 2013/02/02 06:00 [entrez]
PHST- 2013/02/02 06:00 [pubmed]
PHST- 2013/04/10 06:00 [medline]
AID - 10.11150/kansenshogakuzasshi.86.763 [doi]
PST - ppublish
SO  - Kansenshogaku Zasshi. 2012 Nov;86(6):763-7. doi: 
      10.11150/kansenshogakuzasshi.86.763.